A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs IW 1973 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 02 Nov 2017 Status changed from not yet recruiting to recruiting, according to an Ironwood Pharmaceuticals media release.
- 16 Mar 2017 New trial record
- 09 Mar 2017 According to an Ironwood Pharmaceuticals media release, this trial is expected to initiate in the second half of 2017.